YOTI

15.5.2020 13:38:10 CEST | Business Wire | Press release

100% Accurate On-Premise COVID-19 Virus Testing for £10 in 13-25 Minutes. Secure FRANKD Results Shared Using Yoti Digital ID on Phones

GeneMe , a leading biotech company based in Gdańsk, Poland has developed “FRANKD” – a fast, scalable and reliable mouth swab test for COVID-19 that is completed on-premises in on average 13-25 minutes with no laboratory involvement. The GeneMe FRANKD test has been independently validated with 100% Sensitivity and 100% Specificity by Gdańsk University of Technology.

FRANKD requires less time to produce a result than the gold-standard RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) reference test recommended by the World Health Organization. With consent, results are automatically issued on to each individual’s secure, free Yoti digital ID app . The test will cost businesses in the region of £10, making it cost-effective to perform mass daily testing and point-of-entry testing at care homes, airports, offices and many other locations.

Dawid Nidzworski Founder and CEO of GeneMe and developer of FRANKD said:
“We are extremely pleased with the quality of the FRANKD test and the contribution it will make towards the fight against the coronavirus pandemic and its damaging effects on public health and society ”.

FRANKD is currently in talks with governments and businesses across Europe to roll out millions of tests over the coming months, enabling key industries to test hundreds of thousands of employees daily, to help understand the spread of the virus and to monitor the infection R factor more accurately.

The test uses a patented enzyme rather than the currently scarce reagents used in RT-PCR tests to rapidly produce a definitive and reliable result. FRANKD is therefore scalable with 5m monthly tests expected from August. Use of a portable machine analyser to amplify the virus within the sample ensures high test accuracy. During June and July, FRANKD tests will be processed using hundreds of existing analyser machines, able to handle 90 tests every 30 minutes, but GeneMe expects affordable bespoke machines to be available from August.

What differentiates FRANKD from other viral testing solutions is that it is suitable for mass testing; 90 people can be tested at a time, every 30 minutes with one device, massively reducing the cost of testing. Testing on-premises by trained staff removes delays and the challenge of getting test samples to lab technicians to process. Independent validation of the FRANKD test is underway and European CE regulatory certification is expected by early June.

Testing care workers daily could dramatically reduce the spread of infection within the care home sector and beyond. Testing passengers prior to passing through airport security could also prevent disease spread during passenger air travel, reducing the need for mass quarantine. Testing all hotel guests and employees daily could allow hotels to reopen at significantly lower risk. A specific web application from Yoti will ensure all 90 tests within a batch are uniquely assigned to the correct owner before entering the analyser machine.

Individuals use the secure, free Yoti digital ID app to link themselves to their test and, with consent, the digital test result is automatically added into the tested person’s Yoti. Organisations including the NHS already securely issue digital ID cards using the Yoti app credential management platform. Individuals can present or share their tamperproof, verified details with other parties in seconds - including their test result - whether in person or online, with a tap of a button or scan of a QR code.

Anti-fraud measures are built into Yoti’s reusable digital ID, critically offering much higher trust than is possible with traditional paper and plastic-based identity documents or paper health certificates. Audit receipts are issued securely to both the individual and the recipient individual or organisation when results are shared remotely. The Yoti app is currently available in English, with French, Spanish, Polish and German to be released shortly, followed by further languages.

Kasjan Szemiako - CTO of GeneMe and developer of FRANKD said:
“We chose Yoti because of its security, user interface and reputation. We will share the results of the test directly with Yoti to ensure data privacy and enable user control .”

Robin Tombs - Yoti Co-Founder and CEO said:
“We’re delighted FRANKD has chosen Yoti to enable individuals to manage their COVID-19 test results securely on their phone. Getting the world of business and sport back up and running safely during this coronavirus pandemic is so important. Get FRANKD with Yoti.”

===ENDS===

About FRANKD

Contact colin@nexd.partners or visit www.geneme.eu

GeneMe develops, registers and produces diagnostic kits for the detection of SARS-CoV-2 and over 240 other pathogens. All kits are based on direct virus RNA detection in a sample.

GeneMe uses a special patented enzyme for virus detection.
Test results were validated by the Gdańsk University of Technology.
Test Sensitivity results show that the average detection time for a sample containing 1 million viral copies was 12 minutes 45 seconds, and for 10 viral copies was 23 minutes 25 seconds. A German study has reported that an COVID-19 infected individual has an average of 670,000 viral copies per swab during the first 5 days of their illness. https://www.medrxiv.org/content/medrxiv/early/2020/03/08/2020.03.05.20030502.full.pdf
The GeneMe FRANKD test requires less time to produce a result than the gold-standard RT-PCR reference test recommended by the World Health Organization.
Test Specificity results show that no false positives were obtained when testing against 4 other coronaviruses.

FRANKD - stands for Fast, Reliable, Accurate, No laboratory and available in a Kit form to be used on-premises Daily.

Dawid Nidzworski one of the Co-founder’s of GeneMe is also the creator of the Institute of Biotechnology and Molecular Medicine (IBMM).

The Institute of Biotechnology and Molecular Medicine (IBMM) is an independent, elite, biomedical research institution. The thematic scope of IBMM activities includes, among others, biotechnology, medicine, diagnostics, molecular biology and material engineering.

About Business Wire

Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AIM Expands Life Sciences Supply Chain Capabilities and Hires New Partner, Thomas Ebel1.6.2026 15:01:00 CEST | Press release

AIM today announced the appointment of veteran pharma supply chain expert Thomas Ebel as Partner, effective June 15. Mr. Ebel brings more than 25 years of supply chain consulting experience at leading firms including CAMELOT, McKinsey, and Accenture, and will anchor a broader initiative to expand AIM’s end-to-end supply chain capabilities. According to Richard de Bakker, Statutory Director and Founder at AIM, the firm is significantly expanding its capabilities around “end-to-end” supply chain needs. “AIM is well known as a leader in supply chain development for launch, as well as optimization of existing supply chains — supporting clients in getting their finished products to patients,” said Mr. de Bakker. “We are now adding new capabilities in supply chain diagnostics and strategy, end-to-end planning optimization, supply reliability, and working capital optimization, among others. Combined with AIM’s established supply chain expertise, this expanded offering gives clients true ‘end-

Seoul Semiconductor's World-First 'HV Opto-Semiconductor' Powers Up Global Top 4 Automakers1.6.2026 15:00:00 CEST | Press release

Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a global opto-semiconductor technology company, announced that its world's first High Voltage (HV) opto-semiconductor technology has entered mass production with four of the world's top automotive brands across the Americas, Europe, and Asia, with plans to expand supply to 10 models by the end of the year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601232986/en/ Comparison: Conventional 3V LED vs. Seoul Semiconductor 12V 'HV Opto-Semiconductor' (Figure: Seoul Semiconductor) The technology combines micro-scaled opto-semiconductor chips capable of 12V single-chip operation — as opposed to conventional 3V LEDs — with a high-voltage (HV) driver technology. This enables a reduction of more than 10% in the number of driver-related components used in hybrid and electric vehicles, while lowering power consumption by approximately 10%, contributing to cost reduction and simplific

Oscilloquartz delivers assured timing for mission-critical harsh environments with ruggedSync™ Series OSA 55101.6.2026 14:00:00 CEST | Press release

News summary: Defense operations require resilient timing architectures that maintain synchronization in contested and GNSS-denied environments ruggedSync™ Series OSA 5510 delivers assured timing and extended holdover in a MIL-qualified platform for tactical, deployable operations Zero-trust resiliency with diversified cPNT sources, including M-Code, PRS and STL, strengthens operational continuity for defense communications, navigation and mission-critical infrastructure Oscilloquartz today launched its ruggedSync™ Series OSA 5510, a ruggedized timing and synchronization platform engineered for defense and other harsh, mission-critical environments. Designed for deployment in tactical communications networks, mobile command centers (MCCs), aviation systems and other highly demanding operational environments, the OSA 5510 combines PTP grandmaster and NTP server functionality with synchronization assurance and resilient holdover in a compact MIL-qualified platform. Multi-band GNSS suppor

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy1.6.2026 14:00:00 CEST | Press release

- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission for povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in adults with immunoglobulin A nephropathy (IgAN). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging nephrology franchise. “The Phase 3 RAINIER trial is the largest conducted in IgAN and achieved full enrollment faster than any contemporary IgAN trial, reflecting the significant unmet need in IgAN and our urgency to bring povetacicept to patients with this serious disease,” said Nia Tatsis, Ph.D., Executi

Winston Taylor Completes Historic Transatlantic Combination1.6.2026 13:01:00 CEST | Press release

Transatlantic powerhouse law firm established for the businesses, people, and markets driving capital and innovation Winston Taylor announces today that Winston & Strawn and Taylor Wessing’s U.K.-led business have officially launched as a single combined firm, creating a premier transatlantic law firm built for the needs of the businesses, people, and markets driving capital and innovation. One of the largest transatlantic firms, with more than 1,400 lawyers spanning the United States, the United Kingdom, Europe, Latin America, and the Middle East, Winston Taylor is built to meet clients’ evolving global needs for counsel. “As Winston Taylor, we are centered on a client-first approach and will be working shoulder to shoulder with our clients at the cutting edge of industry and ingenuity,” said Chairman Steve D’Amore. “With that common purpose, we are leveraging both strength and scale by integrating our teams and offices at record speed, working at pace to create a firm that is aligned

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom